Binance removes 23 low-liquidity trading pairs as part of routine market quality reviews aimed at enhancing liquidity and user protection.Binance removes 23 low-liquidity trading pairs as part of routine market quality reviews aimed at enhancing liquidity and user protection.

Binance to Remove 23 Spot Trading Pairs in 2026

Key Points:
  • Binance removes 23 low-liquidity trading pairs, affecting market positions.
  • Underlying tokens remain tradable on other pairs.
  • Removal is part of routine liquidity management.
market-adjustments-by-binance-23-low-liquidity-trading-pairs-removed Market Adjustments by Binance: 23 Low-Liquidity Trading Pairs Removed

Binance announced the removal of 23 spot trading pairs due to low liquidity, effective January 9, 2026, at 03:00 UTC, while keeping the underlying tokens on its platform.

This action aims to maintain market quality and user protection, reflecting Binance’s ongoing efforts to optimize trading conditions without delisting tokens entirely.

7 Next 1000x Cryptos to Track in 2026: APEMARS Stage 2 Opens a Rare Window

Whale Transactions in FLOKI Surge by 950% on Ethereum

Market Adjustments by Binance

Binance announced it will remove 23 low-liquidity spot trading pairs on January 9, 2026. The decision aims to maintain a healthy trading environment. The underlying tokens will remain tradable through other pairs on the exchange.

Binance, a key player in the industry, is conducting these actions as part of its routine market quality reviews. No specific leaders are quoted in the announcements, and the move emphasizes liquidity and user protection objectives.

The removal is expected to impact traders who utilize the affected pairs, but the impact on overall token availability is minimized due to other tradable options. ETH and BTC remain unaffected directly but only as quote assets in removed pairs.

The move reflects Binance’s ongoing commitment to market liquidity and quality control. It underlines the exchange’s focus on user protection without drawing from regulatory pressures or funding changes, maintaining unchanged token availabilities in other markets. As stated by the Binance Support Team:

Markets could experience fluctuations in response to these changes, though immediate trading avenues remain open. Binance’s focus remains on enhancing liquidity standards across its platform while periodically reviewing and adjusting its trading offerings.

The removal underscores a historical pattern of periodic pair pruning by Binance. Based on past actions, tokens and liquidity see minor impact, yet align with broader trends to ensure market efficiency and control.

Market Opportunity
Particl Logo
Particl Price(PART)
$0,2874
$0,2874$0,2874
+%9,52
USD
Particl (PART) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26